{"id":"dantrolene-sodium-for-injectable-suspension","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Muscle weakness"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Dyspepsia"},{"rate":"5-10%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL928","moleculeType":"Small molecule","molecularWeight":"336.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action is achieved through its ability to bind to ryanodine receptors, preventing the release of calcium ions and subsequently reducing muscle contraction. As a result, dantrolene sodium is effective in treating conditions characterized by excessive muscle spasticity.","oneSentence":"Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:31:07.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malignant hyperthermia"},{"name":"Spinal cord injury"},{"name":"Stroke"},{"name":"Spinal cord injury associated with autonomic dysreflexia"},{"name":"Cerebral palsy"},{"name":"Multiple sclerosis"},{"name":"Spinal muscular atrophy"},{"name":"Amyotrophic lateral sclerosis"},{"name":"Muscle spasticity associated with cerebral palsy"},{"name":"Muscle spasticity associated with multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02513095","phase":"PHASE2","title":"Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)","status":"COMPLETED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Heat Stroke","enrollment":34},{"nctId":"NCT03600376","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS","status":"COMPLETED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2018-08-19","conditions":"Exertional Heat Stroke","enrollment":17},{"nctId":"NCT03189433","phase":"PHASE2","title":"Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)","status":"TERMINATED","sponsor":"Eagle Pharmaceuticals, Inc.","startDate":"2017-08-12","conditions":"Drug Toxicity Psychotropic Agents Psychostimulants","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ryanodex; EGL-4104"],"phase":"phase_2","status":"active","brandName":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","companyName":"Eagle Pharmaceuticals, Inc.","companyId":"eagle-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity. Used for Malignant hyperthermia, Spinal cord injury, Stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}